Skip to main content

Table 1 Hematologic and hemoglobinic data and Epo levels in thalassemic patients and control subjects.

From: Factors regulating Hb F synthesis in thalassemic diseases

Group of patients N. cases Hb g/dl Hb F % EPO mU/l Glob. synth. alpha/non-alpha Ret. ‰
Sub-silent beta thal int 33 10.1 ± 1.0 20.5 ± 18.2 3.0 → .70.6 41.22 ± 32.00 11.66 → 136.6 2.10 31
Evident beta thal int 41 8.3 ± 1.16 33.40 ± 28.04 6.80 → 85.0 95.83 ± 64.33 17.84 → 218.97 2.20 60
beta thal int in double heterozygous beta thal + triplicated alpha 58 10.0 ± 1.38 5.15 ± 3.9 2.0 → 19.3 28.45 ± 17.11* 7.85 → 60.72 2.50 30
Hb H disease 15 9.4 ± 1.2 < 1 32.88 ± 12.11** 0.52 28
Thal major 24 10.4 ± 1.0 7.7 ± 8.5*** 1.60 → 40.9 46.83 ± 40.78 9.82 → 129.59   17
Healthy non-thal subjects 53 14.4 ± 1.1 <1 11.90 ± 3.3 ~1.0 3
Iron-deficient non-thal subjects 42 8.7 ± 1.2 <1 160.10 ± 312.6 2.7 → 1960.0   8
  1. * The measurement of Epo has been detected only in 17 patients. ** The measurement of Epo has been detected only in 10 patients. *** This value is not informative as patients were routinely transfused.